Daniel Joseph OConnell - Jan 2, 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
President and CEO, Director
Signature
/s/ Derek Meisner, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:18 PM
Previous filing
Jan 18, 2023
Next filing
Jan 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Award $0 +401K +343.66% $0.00 518K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +602K $0.00 602K Jan 2, 2024 Common Stock 602K $4.23 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2 The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.